Patents Assigned to Sunshine Lake Pharma Co., Ltd.
  • SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
    Publication number: 20170073334
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Application
    Filed: September 7, 2016
    Publication date: March 16, 2017
    Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
  • Processes for preparing dihydropyrimidine derivatives and intermediates thereof
    Patent number: 9573941
    Abstract: The present invention relates to processes for preparing a dihydropyrimidine derivative having Formula (I) or a tautomer thereof having Formula (Ia), as well as a intermediate thereof. The processes of the invention have simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: February 21, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun Ren, Xinchang Liu, Zhifu Zou, Guanghua Yan, Mingchao Bi, Siegfried Goldmann, Yingjun Zhang
  • Heteroaromatic compounds as PI3 kinase modulators and methods of use
    Patent number: 9573953
    Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Grant
    Filed: February 15, 2014
    Date of Patent: February 21, 2017
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventor: Ning Xi
  • BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20170044140
    Abstract: Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.
    Type: Application
    Filed: January 22, 2015
    Publication date: February 16, 2017
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Hongming XIE, Jiancun ZHANG, Bailin HU, Qinghong FANG, Qingyun REN
  • Hexahydropentaleno derivatives, preparation method and use in medicine thereof
    Patent number: 9567300
    Abstract: The invention relates to hexahydropentaleno derivatives, the preparation method and use in medicine thereof, and in particular to hexahydropentaleno derivatives or stereo-isomers or pharmaceutically acceptable salts thereof as shown in general formula (I), and to the preparation method therefor and pharmaceutical compositions comprising the derivatives, and to the use thereof as a therapeutical agent, especially as a DPP-IV inhibitor. The definition of each substituent in formula (I) is the same as the definition in the description.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: February 14, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng Gu, Guanpeng Qiu, Wuyong Wu, Panpan Kang, Zongyuan Zhang, Gang Chen, Chengsheng Lan, Yonggang Wei, Jiaping Wen, Guozhi Zhu, Yonghua Lu, Heran Wang, Yincai Wang, Mingyun Yuan, Kangzhi Ye, Guizhuan Su, PengCho Tang
  • Sulfonamide Derivatives And Pharmaceutical Applications Thereof
    Publication number: 20170037017
    Abstract: Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.
    Type: Application
    Filed: April 20, 2015
    Publication date: February 9, 2017
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun ZHANG, Chuanfei JIN, Wenhe ZHONG, Hongpeng XIE, Ji ZHANG
  • Aminoquinazoline derivatives and their salts and methods of use thereof
    Patent number: 9556191
    Abstract: Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: January 31, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Bing Liu, Jinlei Liu, Jiancun Zhang, Changchung Cheng
  • Substituted aminopyrimidine compounds and methods of use
    Patent number: 9518046
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Grant
    Filed: March 15, 2015
    Date of Patent: December 13, 2016
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Liang Wang, Zuping Wu, Xuejin Feng, Yanjun Wu
  • NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS
    Publication number: 20160355501
    Abstract: The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
    Type: Application
    Filed: December 19, 2014
    Publication date: December 8, 2016
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Jiancun Zhang, Xiaojun WANG, Yingjun ZHANG, Runfeng LIN, Yi YU, Liang CHEN, Jihua LIN
  • Substituted aminopyrimidine compounds and methods of use
    Patent number: 9512114
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Grant
    Filed: March 15, 2015
    Date of Patent: December 6, 2016
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Liang Wang, Tingjin Wang
  • DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS
    Publication number: 20160347746
    Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.
    Type: Application
    Filed: March 27, 2015
    Publication date: December 1, 2016
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Qingyun Ren, Xinchang Liu, Siegfried Goldmann
  • Dihydropyrimidine compounds and their application in pharmaceuticals
    Patent number: 9498479
    Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: November 22, 2016
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Xinchang Liu, Zhifu Zou, Jinsheng Liang, Siegfried Goldmann, Qingyun Ren
  • SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
    Publication number: 20160318914
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Application
    Filed: March 15, 2015
    Publication date: November 3, 2016
    Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.
    Inventors: Ning Xi, Liang Wang, Tingjin Wang
  • SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
    Publication number: 20160318913
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Application
    Filed: March 15, 2015
    Publication date: November 3, 2016
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventors: Ning Xi, Liang Wang, Zuping Wu, Xuejin Feng, Yanjun Wu
  • PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF
    Publication number: 20160264563
    Abstract: The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (Ia), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.
    Type: Application
    Filed: November 27, 2014
    Publication date: September 15, 2016
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun REN, Xinchang LIU, Zhifu ZOU, Linjin TU, Yuefeng SHAN, Douxing LEI, Slegfried GOLDMANN, Yingjun ZHANG
  • PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF
    Publication number: 20160264562
    Abstract: The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (la), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.
    Type: Application
    Filed: November 27, 2014
    Publication date: September 15, 2016
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinchang LIU, Qingyun REN, Zhifu ZOU, Jinsheng LIANG, Linjin TU, Siegfried GOLDMANN, Yingjun ZHANG
  • Nitrogenous heterocyclic derivatives and their application in drugs
    Patent number: 9434695
    Abstract: The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: September 6, 2016
    Assignee: SUNSHINE LAKE PHARMA CO., LTD
    Inventors: Yingjun Zhang, Jiancun Zhang, Xiaojun Wang, Runfeng Lin, Shengtian Cao, Zhaohe Wang, Jing Li
  • AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS
    Publication number: 20160251339
    Abstract: Provided herein are novel aromatic heterocyclic compounds or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and methods for using such compounds or pharmaceutical compositions thereof to treat Alzheimer's disease.
    Type: Application
    Filed: December 19, 2014
    Publication date: September 1, 2016
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun ZHANG, Chuanfei JIN, Wenhe ZHONG, Ji ZHANG, Li GAO, Kangzhi CHEN
  • SOLID FORM OF PYRAZOLOPYRIDINE COMPOUND
    Publication number: 20160251349
    Abstract: A novel crystalline form or amorphous of formula (I) and preparation method thereof are disclosed in present invention, wherein the novel crystalline form is substantially pure crystalline form I, form II, form III or form IV. The novel crystalline forms disclosed herein have good solubility, low hydroscopicity and good stability at high temperature (60° C.), high humidity (RH is 90%±5%) and/or under light (4500+/?500 Lux), which benefit for storage, meet the requirements of drug stability and therefore, making formula (I) suitable for formulation preparation and with high bioavailability.
    Type: Application
    Filed: October 15, 2014
    Publication date: September 1, 2016
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Shouzhu LIAO, Weijie FAN, Zhongqing WANG
  • Substituted Piperazine Compounds And Methods Of Use Thereof
    Publication number: 20160244429
    Abstract: Provided herein are novel piperazine compounds and pharmaceutical compositions thereof comprising the piperazine compounds for inhibiting serotonin reuptake and/or acting as 5-HT1A receptor agonists. Also provided herein are methods for preparing the novel piperazine compounds and pharmaceutical compositions thereof, and uses of them in treating central nervous system (CNS) dysfunction.
    Type: Application
    Filed: December 19, 2014
    Publication date: August 25, 2016
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun Zhang, Chuanfei JIN, Rongqi ZHOU